Elevated IL-37 Serum Levels in Patients with Transitional Cell Carcinoma of Bladder.
Mohammad Reza HaghshenasSeyed Reza HosseiniMohammad Javad FattahiMahyar MalekzadehAli AriafarAbbas GhaderiPublished in: Iranian journal of immunology : IJI (2022)
The findings reveal a higher serum level of IL-37 in patients with TCC, which might be clinically associated with immunosuppression and tumor growth. However, this is a preliminary study, and more research on the biological role of IL-37 and its potential therapeutic effects in bladder cancer is required.